Newsroom
Latest News
WASHINGTON, D.C. – U.S. Rep. Diana DeGette (D-CO), chair of the House oversight panel that's investigating the skyrocketing cost of insulin, announced today that all three U.S. manufacturers of insulin will be appearing before Congress next week.
The only three companies that manufacture insulin in the United States will testify in the House next week about their pricing practices.
Rep. Diana DeGette (D-Colo.), chairwoman of the House Energy and Commerce oversight subcommittee, said the three companies— Eli Lilly, Novo Nordisk and Sanofi— will testify April 10.
U.S. Representative Diana DeGette's bill to halt federal marijuana prohibition in states where cannabis is legal was introduced on Monday, April 1, but she insists the issue is no joke.
Colorado's Rep. Diana DeGette, representing the 1st Congressional District, introduced a bill aimed at bringing down the cost of insulin. The bill would make permanent a new FDA policy which would speed up the approval of generic version of certain drugs.
That would include insulin.
DeGette met with Colorado patients to talk about their struggle the cost of insulin.
WASHINGTON, D.C. – U.S. Rep. Diana DeGette (D-CO) introduced legislation today that would prevent the federal government from enforcing its prohibition on marijuana in states, such as Colorado, where it is legal for residents to possess and use the drug.
WASHINGTON, D.C. – A bipartisan group of lawmakers introduced legislation today seeking to bring down the cost of certain biologic drugs, such as insulin, by making it easier for drug makers to get generic versions of those drugs approved by the Food and Drug Administration.
Insulin users say the skyrocketing cost of the drug is forcing them to make some tough decisions. Rep. Diana DeGette met with some diabetics in Colorado this week to discuss the issue.
WASHINGTON, D.C. – U.S. Rep. Diana DeGette (D-CO), chair of the House oversight panel that's currently investigating the rising cost of insulin, announced today that her committee will hold its first of two hearings on the skyrocketing cost of the drug next Tuesday, April 2, at 10:30 a.m. ET.